Skip to main content
. 2016 Jan 22;11(1):e0147067. doi: 10.1371/journal.pone.0147067

Fig 3. miR-134 regulates ECFC motility and microvasculature formation ability.

Fig 3

(A) Representative images (left) and quantitative data (right) from the Transwell migration assays (upper) and tube formation assays (lower) of dfECFCs with miR-370 and miR-134 overexpression. n = 3 independent experiments. * p < 0.05 by one-way ANOVA followed by Tukey’s post-hoc test. Scale bar: 50 μm (B) The expression levels of miR-134 under osmotic culture condition (NG) or under high glucose condition (HG) treated with scramble control and miR-134 antagomir (Anti-134) in dfECFCs as quantified by RT-qPCR. * p < 0.05 by one-way ANOVA followed by Tukey’s post-hoc test n = 3 independent experiments. (C) Cellular migration assays (left) and tube formation assays (right) of NG-dfECFCs and HG-dfECFCs after scramble control and miR-134 antagomir (Anti-134) treatment. n = 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 by one-way ANOVA followed by Tukey’s post-hoc test. (D) Expression levels of miR-134 in dfECFCs or antagomir treated dmECFCs using RT-qPCR. n = 3 independent experiments. * p < 0.05 by one-way ANOVA followed by Tukey’s post-hoc test. (E) Representative images (lower) and quantitative data (upper) from the Transwell migration assays and tube formation assays of dfECFCs and antagomir treated dmECFCs. n = 3 independent experiments. * p < 0.05, ** p < 0.01 by one-way ANOVA followed by Tukey’s post-hoc test. Scale bar: 50 μm. Vec, plasmid control; Scr, scramble; Anti-134, miR-134 antagomir.